eptinezumab is in phase iii trials. its maker plans to submit an application with the fda later this year. it is for chronic migraine prevention.
.most recent
.
powered by delhi times, aurangabad times, maharashtra times
.
.
�we have waited a long time and we cannot possibly wait any longer.�
.
.
scottish widows' figures were compiled using the abi guidance for calculating claims statistics.
.